A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

Next Previous
Trial Profile

A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis Pharma A.G.

    • Most Recent Events

    • 03 Nov 2017 Planned End Date changed from 1 Aug 2016 to 1 Dec 2020.
    • 11 Sep 2017 Results from this trial presented at the 2017 European Society of Medical Oncology Congress(ESMO) Madrid, Spain, according to a Novartis media release.
    • 11 Sep 2017 Results published in a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top